OBJECTIVE: The purpose of this study was to compare the time-course of contrast-enhancement in spleen and liver using Exia 160 in comparison with Fenestra LC and VC in healthy mice. PROCEDURES: Healthy C57bl/6 mice were used in this study. Fenestra LC and VC was administered intravenously at a dose of 0.1 ml/20 g or 0.2 ml/20 g. Exia 160 at a dose of 0.05 ml/20 g or 0.1 ml/20 g. Each animal underwent a micro-CT scan before contrast injection (baseline) and immediately after contrast injection. Additional scans were performed at 1, 2, 3, 4, 24, and 48 h after contrast administration. The mice who received Exia 160 were also scanned after 15, 30, and 45 min. RESULTS: The peak enhancement of Exia 160 occurred after 15 min for the spleen and after 30 min for the liver. CONCLUSIONS: Exia 160 allows rapid spleen and liver enhancement. The high iodine content results in small injection volumes.
OBJECTIVE: The purpose of this study was to compare the time-course of contrast-enhancement in spleen and liver using Exia 160 in comparison with Fenestra LC and VC in healthy mice. PROCEDURES: Healthy C57bl/6 mice were used in this study. Fenestra LC and VC was administered intravenously at a dose of 0.1 ml/20 g or 0.2 ml/20 g. Exia 160 at a dose of 0.05 ml/20 g or 0.1 ml/20 g. Each animal underwent a micro-CT scan before contrast injection (baseline) and immediately after contrast injection. Additional scans were performed at 1, 2, 3, 4, 24, and 48 h after contrast administration. The mice who received Exia 160 were also scanned after 15, 30, and 45 min. RESULTS: The peak enhancement of Exia 160 occurred after 15 min for the spleen and after 30 min for the liver. CONCLUSIONS: Exia 160 allows rapid spleen and liver enhancement. The high iodine content results in small injection volumes.
Authors: Dawn Cavanaugh; Evan Johnson; Roger E Price; Jonathan Kurie; Elizabeth L Travis; Dianna D Cody Journal: Mol Imaging Date: 2004-01 Impact factor: 4.488
Authors: Nancy L Ford; Kevin C Graham; Alan C Groom; Ian C Macdonald; Ann F Chambers; David W Holdsworth Journal: Invest Radiol Date: 2006-04 Impact factor: 6.016
Authors: Nora M De Clerck; Kris Meurrens; Horst Weiler; Dirk Van Dyck; Greet Van Houtte; Piter Terpstra; Andrei A Postnov Journal: Neoplasia Date: 2004 Jul-Aug Impact factor: 5.715
Authors: Andreas Schmid; Jennifer Schmitz; Julia G Mannheim; Florian C Maier; Kerstin Fuchs; Hans F Wehrl; Bernd J Pichler Journal: Mol Imaging Biol Date: 2013-04 Impact factor: 3.488
Authors: Mohamed F Attia; Nicolas Anton; Roman Akasov; Manuela Chiper; Elena Markvicheva; Thierry F Vandamme Journal: Pharm Res Date: 2015-10-28 Impact factor: 4.200
Authors: Jeffrey R Ashton; Nicholas Befera; Darin Clark; Yi Qi; Lan Mao; Howard A Rockman; G Allan Johnson; Cristian T Badea Journal: Contrast Media Mol Imaging Date: 2014 Mar-Apr Impact factor: 3.161